| Symbol | TNXP |
|---|---|
| Name | TONIX PHARMACEUTICALS HOLDING CORP. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 CONNELL DRIVE, BERKELEY HEIGHTS, New Jersey, 07922, United States |
| Telephone | +1 862 - 799-8599 |
| Fax | — |
| — | |
| Website | https://www.tonixpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001430306 |
| Description | Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonixs immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonixs rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Tonix Pharmaceuticals Holding Corp. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005208 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G - Tonix Pharmaceuticals Holding Corp. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001167557-26-000168 <b>Size:</b> 8 KB
Read more(99% Neutral) TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Reports Q3 2026 Financial Results
Read moreTonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Read moreTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Read moreTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Read moreTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Read moreTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Read more